Abstract Background Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited. In most cases. they are not amenable to local therapies including surgery or radiofrequency ablation. The multi-kinase inhibitor sorafenib has shown to increase overall survival in this patient group for about 3 months. https://fitnessgravesyardes.shop/product-category/right-pedal-arm/